

# Lin Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3626918/publications.pdf>

Version: 2024-02-01

8  
papers

1,672  
citations

1307594

7  
h-index

1588992

8  
g-index

10  
all docs

10  
docs citations

10  
times ranked

4217  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: a phase 4, single-center, randomized controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5348-5354.	3.3	5
2	Novel nanostructure-coupled biosensor platform for one-step high-throughput quantification of serum neutralizing antibody after COVID-19 vaccination. <i>Biosensors and Bioelectronics</i> , 2022, 199, 113868.	10.1	16
3	Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. <i>Nature</i> , 2022, 603, 919-925.	27.8	146
4	Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 483-495.	9.1	232
5	Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials. <i>Nature Communications</i> , 2022, 13, .	12.8	19
6	Over 1-year duration and age difference of SARS-CoV-2 antibodies in convalescent COVID-19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 6506-6511.	5.0	26
7	Immunological evaluation of an inactivated SARS-CoV-2 vaccine in rhesus macaques. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 108-118.	4.1	9
8	Development of an inactivated vaccine candidate for SARS-CoV-2. <i>Science</i> , 2020, 369, 77-81.	12.6	1,180